Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 16 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 11530236

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  2. US 11529347

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  3. US 11524962

    Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  4. US 11518750

    3-methylideneoxan-4-one compounds and substituted derivatives thereof as inhibitors of telomerase

    Northwestern University · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  5. US 11518772

    Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  6. US 11512309

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  7. US 11504364

    Inhibitors of fibroblast activation protein

    PRAXIS BIOTECH LLC · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  8. US 11504390

    Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  9. US 11497740

    Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer

    The Board of Regents of the University of Texas System · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  10. US 11497734

    Dual inhibitors of TIM-3 and PD-1 pathways

    Aurigene Discovery Technologies Limited · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  11. US 11498905

    Inhibitors of platelet function and methods for use of the same

    The Regents of the University of California · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  12. US 11498928

    Macrocyclic spiroethers as Mcl-1 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  13. US 11492351

    MTA-cooperative PRMT5 inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  14. US 11492349

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  15. US 11485760

    Inhibitors of CRISPR-Cas9

    The Regents of the University of California · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  16. US 11485738

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  17. US 11485739

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  18. US 11479770

    Use of p38 inhibitors to reduce expression of DUX4

    Fulcrum Therapeutics, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  19. US 11479551

    MTA-cooperative PRMT5 inhibitors

    Mirati Therapeutics, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  20. US 11479543

    Heterocyclic RIP1 kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  21. US 11471528

    Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

    The Government of the United States of America as represented by the Secretary of the Department · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  22. US 11465972

    Inhibitors of oxidized low-density lipoprotein receptor 1 and methods of use thereof

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  23. US 11466017

    Heterocyclic inhibitors of PTPN11

    The Board of Regents of the University of Texas System · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  24. US 11464774

    Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted